Editas Medicine Inc EDIT

NAS: EDIT | ISIN: US28106W1036 30/04/2025

1,650 USD (+6,45%)

(+6,45%) 30/04/2025

Grafiek Editas Medicine Inc

Grafiek Editas Medicine Inc

1 dag1d 6,45%
1 week1w 2,48%
1 maand1m 46,02%
3 maanden3m 29,92%
6 maanden6m -43,30%
1 jaar1j -69,84%
5 jaar5j -92,57%

Editas Medicine Inc in het nieuws

Toon enkel gratis nieuws

27 juli 2023 · Editas Medicine and Azzur Group Expand Partnership to Accelerate Editas' Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization · Persbericht

18 februari 2021 · Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2020 Results and Corporate Update · Persbericht

21 januari 2021 · Editas Medicine Announces Pricing of Offering of Common Stock · Persbericht

19 januari 2021 · Editas Medicine Announces Offering of Common Stock · Persbericht

11 januari 2021 · Editas Medicine Reports on Recent Progress and Outlook at J.P. Morgan Healthcare Conference · Persbericht

11 januari 2021 · Editas Medicine Announces the FDA has Cleared Initiation of the EDIT-301 Clinical Trial · Persbericht

11 januari 2021 · Editas Medicine Announces Transition of Chief Scientific Officer · Persbericht

4 januari 2021 · Editas Medicine to Present at the 39th Annual J.P. Morgan Healthcare Conference · Persbericht

Profiel Editas Medicine Inc

Gezondheidstechnologie

Productie van biologische producten

Website: www.editasmedicine.com

Hoofdzetel: Cambridge, Massachusetts Verenigde Staten

CEO: Cynthia Collins

Werknemers: 297

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe